Patents Examined by Elly-Gerald Stoica
  • Natural killer cell function enhancer
    Patent number: 11325961
    Abstract: To provide a therapy and a diagnosis of cancer or an infection using recognition mechanism of a T-cell receptor.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: May 10, 2022
    Assignee: TOHOKU UNIVERSITY
    Inventor: Koetsu Ogasawara
  • Cross-species anti-latent TGF-beta 1 antibodies
    Patent number: 11312767
    Abstract: The objective of the invention is to provide cross-species anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1. To obtain the anti-latent TGF-beta 1 antibodies of the invention, anti-latent-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1 were screened, and then humanized, and further optimized. The invention also provides combination therapies comprising an anti-latent TGF-beta 1 antibody and one or more immune checkpoint inhibitors, preferably a PD-1 axis binding antagonists.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: April 26, 2022
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Chugai Pharmabody Research Pte. Ltd.
    Inventors: Hideaki Shimada, Masakazu Kanamori, Xing'er Christine Koo
  • Combination immunotherapies comprising IL-15 superagonists
    Patent number: 11304998
    Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: April 19, 2022
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Adrian Rice, Elizabeth Gabitzsch, Yvette Latchman, Joseph Balint
  • Bispecific antibodies to ROR1 and CD3
    Patent number: 11306142
    Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 19, 2022
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • p53-BAD fusion proteins
    Patent number: 11299526
    Abstract: Disclosed are peptides comprising a p53 peptide and a BH3-only protein. In some aspects, wherein the BH3-only protein is BAD, BID, BIM, NOXA. Disclosed are nucleic acid sequences comprising a sequence capable of encoding a p53 peptide operably linked to a nucleic acid sequence capable of encoding a BH3-only protein. Disclosed are nucleic acid sequences comprising a sequence capable of encoding one or more of the peptides disclosed herein. Disclosed are vectors comprising a nucleic acid sequence, wherein the nucleic acid sequence is capable of encoding one or more of the peptides disclosed herein. Also disclosed are methods of using the disclosed peptides, nucleic acid sequences, and vectors.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: April 12, 2022
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Carol S. Lim, Phong Lu
  • Mesoporous silica compositions comprising inflammatory cytokines comprising inflammatory cytokines for modulating immune responses
    Patent number: 11278604
    Abstract: A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: March 22, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Jaeyun Kim, Weiwei Aileen Li, David J. Mooney
  • Compositions and methods to improve anti-angiogenic therapy and immunotherapy
    Patent number: 11279765
    Abstract: Agents that inhibit CX3CL1 in endothelial cells to reduce or inhibit immunosuppression mechanisms that are co-opted by cancer cells to evade host immune system, and that reduce immunosuppression in context of therapies that target VEGF-dependent signaling, and methods of use thereof.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: March 22, 2022
    Assignee: The General Hospital Corporation
    Inventors: Dai Fukumura, Keehoon Jung, Rakesh K. Jain
  • IL-15 protein complex pharmaceutical composition
    Patent number: 11273205
    Abstract: The present disclosure relates to a pharmaceutical composition, which comprises an IL-15 protein complex and a citrate buffer solution. In addition, the pharmaceutical composition may also comprise a sugar and a non-ionic surfactant. The pharmaceutical composition in the present disclosure demonstrates a high degree of stability even after being stored at 2-8° C. for several months.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: March 15, 2022
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Tingting Wu, Hao Li, Xun Liu
  • CSF1R-CD40L chimeric proteins
    Patent number: 11267856
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Ultra-potent neutralization of GM-CSF by multispecific antibodies and uses thereof
    Patent number: 11261245
    Abstract: The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 1, 2022
    Assignee: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Davide Corti, Antonio Lanzavecchia, Luca Piccoli
  • Immunogenic peptide composition
    Patent number: 11260118
    Abstract: The present invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. Particularly, the peptide composition comprises at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. The present invention further relates to the use of a peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 1, 2022
    Assignee: Cancer Research Malaysia
    Inventors: San Jiun Chai, Sammuel Chee Yong Fong, Chai Phei Gan, Sathibalan Ponniah, Vyomesh Patel, Sok Ching Cheong, Kue Peng Lim
  • Methods for depleting or inhibiting the migration of regulatory T-cells in early or late stages of cancer
    Patent number: 11261256
    Abstract: The present disclosure provides methods of modulating regulatory T-cell activity and function.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: March 1, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventor: Wayne A. Marasco
  • Anti-human migration stimulating factor (MSF) and uses thereof
    Patent number: 11254739
    Abstract: The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: February 22, 2022
    Assignee: HUMANITAS MIRASOLE S.P.A.
    Inventors: Alberto Mantovani, Barbara Bottazzi, Ilaria Laface, Antonio Inforzato, Tamara Gulic
  • Anti-IL1RAP antibodies and antibody drug conjugates
    Patent number: 11248054
    Abstract: Disclosed herein are Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 15, 2022
    Assignee: BLUEFIN BIOMEDICINE, INC.
    Inventors: Tinglei Gu, Scott Michael Lonning, Jason G. Beaudet, Sean A. Beausoleil, Nels Eric Pederson, Daniel Mulhern
  • Combination immunotherapy dosing regimen for immune checkpoint blockade
    Patent number: 11235032
    Abstract: The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: February 1, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Chensu Wang, Karl Dane Wittrup, Darrell J. Irvine
  • Afucosylated anti-FGFR2IIIB antibodies
    Patent number: 11235059
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: February 1, 2022
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • Immunogenic compositions comprising nucleic acids for RAS peptides
    Patent number: 11235039
    Abstract: The present disclosure provides for methods, systems, and compositions of nucleic acid and peptide sequences. The present disclosure provides for a nucleic acid sequence encoding two or more amino acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, and SEQ ID NO: 41.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: February 1, 2022
    Assignee: Think Therapeutics, Inc.
    Inventors: David Gifford, Brandon Carter
  • Methods of producing an IL-1 RAP antibodies
    Patent number: 11236172
    Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 1, 2022
    Assignee: CANTARGIA AB
    Inventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin Von Wachenfeldt
  • Antibodies against ILT2
    Patent number: 11236162
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: February 1, 2022
    Assignee: Biond Biologies Ltd.
    Inventors: Ilana Mandel, Tsuri Peretz, Dana Haves Ziv, Ilana Goldshtein, Dror Alishekevitz, Anna Fridman-Dror, Motti Hakim, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe
  • Anti-GARP protein
    Patent number: 11230603
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: January 25, 2022
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBA
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck